Analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX – Get Free Report) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.
Separately, Benchmark restated a “hold” rating on shares of VolitionRx in a research note on Friday, August 16th.
Read Our Latest Research Report on VNRX
VolitionRx Stock Down 1.8 %
VolitionRx (NYSE:VNRX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.34 million. As a group, research analysts expect that VolitionRx will post -0.31 EPS for the current fiscal year.
Insider Activity at VolitionRx
In related news, Director Guy Archibald Innes purchased 150,000 shares of VolitionRx stock in a transaction dated Tuesday, August 20th. The stock was bought at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the completion of the transaction, the director now owns 406,683 shares in the company, valued at $272,477.61. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.80% of the stock is currently owned by corporate insiders.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Read More
- Five stocks we like better than VolitionRx
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- The How And Why of Investing in Oil Stocks
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What does consumer price index measure?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.